Research progress on peroxisome proliferator activated receptor γ and systemic lupus erythematosus

Corresponding author: Li Xin, 543679618@qq.com

DOI: 10.12201/bmr.202505.00007

•  

  Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with complex clinical manifestations. Because the pathogenesis of this disease is not completely clear, and the individual differences between patients are large, the existing treatment methods are limited. Peroxisome proliferator activated receptor γ (PPAR γ) is the most widely studied member of PPAR subfamily, which is involved in regulating adipocyte differentiation, glucose metabolism, inflammatory response, immune regulation and other life activities. Some recent studies have shown that PPAR γ agonists may be potential drugs for the treatment of SLE. This article reviews the latest research progress of PPAR γ in SLE, aiming to provide new insights and theoretical basis for the treatment of SLE.

  Key words: Peroxisome proliferator activated receptor γ, Systemic lupus erythematosus, Rosiglitazone, Pioglitazone

  Submit time: 11 May 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• ZHANG xin, NING Jinghua, QUrun, ZHANG Yuzhe. Mendelian randomization combined with transcriptome identification of key causative genes in systemic lupus erythematosus. 2025. doi: 10.12201/bmr.202502.00062

  YANG Di, HE Jing, YAN Xiao.. A case of Systemic lupus erythematosus secondary to thrombotic thrombocytopenic purpura combined with pregnancy and review of the literature. 2025. doi: 10.12201/bmr.202504.00053

  郭玥, WANG Xu. Treatment of systemic lupus erythematosus based on the principle of “treating the balance of power and weights and removing the chopsticks of Wan Chan”. 2025. doi: 10.12201/bmr.202506.00014

  jinziran, liyan, liuxuan, sunhaotian, gaojing. . 2024. doi: 10.12201/bmr.202412.00021

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  Liu Yanan, Zhan Ming, Han Fei. Research Progress and Prospects of Finerenone in the Treatment of Diabetic Nephropathy. 2024. doi: 10.12201/bmr.202410.00033

  Liu Xiaoying, Xu Kefei. A case of treating lupus nephritis in a child with Belizumab combined with traditional Chinese medicine syndrome differentiation formula. 2024. doi: 10.12201/bmr.202409.00041

  Changes of lipid peroxidation and antioxidant capacity in patients with hypercholesterolemia. 2024. doi: 10.12201/bmr.202409.00053

  ZHANG Xiaoling, CHEN Kun. The value of systemic inflammatory response index, lactate dehydrogenase and glutamic oxalacetic transaminase in identifying the high-risk population of adult fulminant myocarditis. 2024. doi: 10.12201/bmr.202410.00070

  NIU Xiao Shan. Advances in pharmacological studies of NF-κB involved in the regulation of nonalcoholic fatty liver disease. 2024. doi: 10.12201/bmr.202410.00006

• ID	Submit time	Number	Download
  1	2025-03-04	bmr.202505.00007V1	Download

• Public  Anonymous  To author only Submit Comments